Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Emactuzumab |
| Trade Name | |
| Synonyms | RG7155|RO5509554 |
| Drug Descriptions |
Emactuzumab (RG7155) is a monoclonal antibody that inhibits dimerization of CSF1R, resulting in decreased ligand-dependent and ligand-independent signaling, thereby potentially leading to reduced tumor growth (PMID: 24898549, PMID: 32575160, PMID: 31114846). |
| DrugClasses | CSF1R Inhibitor 28 |
| CAS Registry Number | 1448221-67-7 |
| NCIT ID | C125548 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Emactuzumab | Atezolizumab Emactuzumab | 0 | 3 |
| Bevacizumab + Emactuzumab + Paclitaxel | Bevacizumab Emactuzumab Paclitaxel | 0 | 1 |
| Emactuzumab | Emactuzumab | 0 | 2 |
| Emactuzumab + Paclitaxel | Emactuzumab Paclitaxel | 0 | 1 |
| Emactuzumab + Selicrelumab | Emactuzumab Selicrelumab | 0 | 1 |